June 19, 2021 5:13 pm Published by admin SUMMARY This phase II trial studies the effect of belinostat and SGI-110 (guadecitabine) combination therapy in treating patients with conventional chondrosarcoma that cannot be removed by surgery (unresectable) and has spread to other places in the body (metastatic). Belinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell [...]
June 3, 2021 1:38 am Published by admin Check out the video hosted by Memorial Sloan Kettering entitled: Empowering Patients: Speak Up for Your Health. The Empowered Patient: Speak Up for Your Health | Memorial Sloan Kettering Cancer Center (mskcc.org) Transcript: Barbra Rothschild: Hello, everybody. Welcome to the special information session hosted by MSK’s Patient and Family Advisory Council for Quality in collaboration [...]
May 26, 2021 6:01 pm Published by admin Targeted Cancer Therapies ON THIS PAGE What are targeted cancer therapies? How are targets for targeted cancer therapies identified? How are targeted therapies developed? What types of targeted therapies are available? How is it determined whether a patient is a candidate for targeted therapy? What are the limitations of targeted cancer therapies? What are the [...]
May 25, 2021 2:05 am Published by admin Check out the video hosted by Memorial Sloan Kettering entitled: Empowering Patients: Speak Up for Your Health. The link is listed below as well as the transcript. The Empowered Patient: Speak Up for Your Health | Memorial Sloan Kettering Cancer Center (mskcc.org) Transcript: Barbra Rothschild: Hello, everybody. Welcome to the special information session hosted by [...]
May 16, 2021 7:58 pm Published by admin SAN DIEGO, Nov. 11, 2020 /PRNewswire/ —InhibRx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, announced updated interim results today from a Phase 1 clinical trial evaluating the efficacy and safety of INBRX-109 in patients with chondrosarcoma. This data will be presented to attendees of the Annual Connective Tissue Oncology Society [...]
May 8, 2021 7:58 pm Published by admin This coming Friday will be the Chondrosarcoma Foundation’s first anniversary. Last year, on May 14, 2020 during the beginning of the pandemic, we launched the Chondrosarcoma Foundation by bringing CS Foundation web site on-line. My daughter Shayna Elise Kramer expressed a desire to educate the world about Chondrosarcoma so she could help others suffering from [...]
May 7, 2021 10:28 pm Published by admin November 13, 2020 Dylann Cohn-Emery Treatment with the investigation agent INBRX-109 induced responses and decreased the tumor burden in a cohort of patients with chondrosarcoma, according to interim efficacy and safety findings a phase 1 trial in patients with chondrosarcoma, Inhibrx, Inc announced in a press release. Treatment with the investigation agent INBRX-109 induced responses [...]
May 7, 2021 10:28 pm Published by admin Inhibrx Granted Fast Track Designation for INBRX-109 for the Treatment of Unresectable or Metastatic Conventional Chondrosarcoma Patients Registration-enabling study expected to begin dosing in the second or third quarter of this year
April 30, 2021 5:48 pm Published by admin Elena Cojocaru, Christopher Wilding, Bodil Engelman, Paul Huang & Robin L. Jones Current Molecular Biology Reports volume 6, pages1–9(2020)Cite this article Is the IDH Mutation a Good Target for Chondrosarcoma Treatment? | SpringerLink detail Abstract Chondrosarcomas are rare cancers of bone that arise from the malignant transformation of cells of chondrocytic lineage. They are known [...]
April 30, 2021 4:41 pm Published by admin Abstract Dioxins are ubiquitous and persistent environmental contaminants whose background levels are still reason for concern. There is mounting evidence from both epidemiological and experimental studies that paternal exposure to the most potent congener of dioxins, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), can lower the male/female ratio of offspring. Moreover, in laboratory rodents and zebrafish, TCDD exposure of parent [...]
